Skip to main content
Log in

Salmeterol/Fluticasone Propionate

A Review of its Use in Asthma

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Salmeterol/fluticasone propionate (Seretide/Advair Diskus® [dry powder inhaler] or Seretide/Advair® inhalation aerosol [metered-dose inhaler]) is a fixed-dose combination inhalation agent containing a long-acting β2-adrenoceptor agonist (LABA) plus a corticosteroid. In patients with symptomatic asthma, twice-daily salmeterol/fluticasone propionate maintenance therapy improves lung function and asthma symptoms to a greater extent than monotherapy with inhaled corticosteroids (ICS), such as fluticasone propionate, oral montelukast with or without fluticasone propionate, or sustained-release theophylline plus fluticasone propionate. The greater efficacy achieved with salmeterol/fluticasone propionate versus fluticasone propionate alone was sustained for 1 year in a well designed trial. Salmeterol/fluticasone propionate is also associated with a corticosteroid-sparing effect. Results of studies comparing fixed dosages of salmeterol/fluticasone propionate with formoterol/budesonide in adults and adolescents are equivocal. Twice-daily salmeterol/fluticasone propionate is associated with clinically meaningful improvements from baseline in health-related quality of life (HR-QOL), and improvements were greater than those reported with fluticasone propionate alone. Salmeterol/fluticasone propionate is generally well tolerated in adults, adolescents and children aged 4–11 years, and the fixed-combination inhaler ensures the appropriate use of a LABA in combination with an ICS. In cost-utility analyses in patients with uncontrolled asthma, salmeterol/fluticasone propionate compares favourably with fluticasone propionate alone or oral montelukast. Thus, salmeterol/fluticasone propionate provides an effective, well tolerated and cost-effective option for maintenance treatment in patients with asthma.

Pharmacological Properties

Salmeterol is a selective LABA, which causes bronchodilation and inhibition of the release of hypersensitivity mediators from mast cells. The corticosteroid fluticasone propionate inhibits eosinophil activation and the subsequent release of inflammatory mediators. Coadministration of inhaled salmeterol and fluticasone propionate produce similar effects to those observed when the two agents are administered separately, and in vitro studies suggest beneficial additive or synergistic effects.

The pharmacokinetics of concomitant salmeterol and fluticasone propionate are generally similar to those recorded following individual administration, with no systemic pharmacokinetic interaction. The action of inhaled salmeterol or fluticasone propionate is local to the lung, so plasma levels are not an indication of therapeutic effect. Salmeterol is extensively metabolized via hydroxylation, and fluticasone propionate is principally metabolized to an inactive metabolite by the cytochrome P450 (CYP) isoenzyme CYP3A4.

Therapeutic Efficacy

Salmeterol/fluticasone propionate maintenance therapy improves lung function and asthma symptoms to a greater extent than monotherapy with ICS or montelukast in adults, adolescents and children aged 4–11 years with symptomatic asthma. In well designed, long-term studies of up to 1 year, twice-daily salmeterol/fluticasone propionate achieved better asthma control than twice-daily fluticasone propionate alone. The combination of salmeterol/fluticasone propionate has a corticosteroid-sparing effect, with twice-daily salmeterol/fluticasone propionate 50 μg/100 μg maintaining a level of control that was not significantly different to that achieved with twice-daily fluticasone propionate 250 μg. Twice-daily salmeterol/fluticasone propionate in a single inhaler was as effective as the same dosages of twice-daily salmeterol plus fluticasone propionate administered concurrently in separate inhalers.

Results of studies comparing salmeterol/fluticasone propionate with formoterol/budesonide maintenance therapy in adults and adolescents have been mixed, with some showing similar efficacy and others demonstrating greater efficacy with either agent. Twice-daily salmeterol/fluticasone propionate provided more effective control of asthma symptoms than twice-daily sustained-release theophylline plus fluticasone propionate. Clinically meaningful improvements from baseline in HR-QOL have been observed in asthmatics treated with twice-daily salmeterol/fluticasone propionate. Asthma quality-of-life questionnaire scores were improved more with salmeterol/fluticasone propionate than with fluticasone propionate alone or oral montelukast, but results from HR-QOL studies comparing salmeterol/fluticasone propionate with formoterol/budesonide were mixed.

In patients with uncontrolled asthma, salmeterol/fluticasone propionate was cost effective compared with monotherapy with fluticasone propionate or oral montelukast, with regard to the incremental cost per quality-adjusted life-year gained, per symptom- or rescue-free day, or cost per 12% improvement in forced expiratory volume in 1 second, but results of studies comparing salmeterol/fluticasone propionate with formoterol/budesonide were mixed.

Tolerability

Salmeterol/fluticasone propionate is generally well tolerated in adults, adolescents and children and, overall, the most frequent treatment-related adverse effects include upper respiratory tract infection, pharyngitis, headaches and throat irritation/cough. In clinical trials, the incidence of treatment-related effects was generally similar to that of comparators, including fluticasone propionate alone, montelukast or formoterol/budesonide.

In a well designed, 12-week study in asthmatic children aged 6–14 years, the most common adverse event associated with salmeterol/fluticasone propionate or oral motelukast was headache. The incidence of treatment-related adverse effects was 2% in each treatment group, with serious events reported in zero and three patients, respectively. Urinary cortisol excretion over 24 hours remained within normal limits after 12 weeks of treatment with salmeterol/fluticasone propionate 50 μg/100 mg in children aged 4–11 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Table IV
Table V
Table VI
Table VII

Similar content being viewed by others

References

  1. Jeffery P. Inflammation and remodeling in the adult and child with asthma. Pediatr Pulmonol 2001; 21 Suppl.: 3–16

    Article  CAS  Google Scholar 

  2. Masoli M, Fabian D, Holt S, et al. Global burden of asthma. Developed for the Global Inititive for Asthma [online]. Available from URL: http://www.ginasthma.com/ReportItem.asp?1I=2&intId=94 [Accessed 2009 May 29]

  3. Global Initiative for Asthma. Global strategy for asthma management and prevention. GINA report: global strategy for asthma management and prevention (updated 2007) [online]. Available from URL: http://www.ginasthma.com/Guidelineitem.asp?1=2&12=1&intId=1561 [Accessed 2009 Apr 28]

  4. Reynolds NA, Lyseng-Williamson KA, Wiseman LR. Inhaled salmeterol/fluticasone propionate: a review of its use in asthma. Drugs 2005; 65(12): 1715–34

    Article  PubMed  CAS  Google Scholar 

  5. Adkins JC, McTavish D. Salmeterol: a review of its pharmacological properties and clinical efficacy in the management of children with asthma. Drugs 1997; 54(2): 331–54

    Article  PubMed  CAS  Google Scholar 

  6. Jarvis B, Faulds D. Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages <500 μg/day in adults and adolescents with mild to moderate asthma. Drugs 1999; 57(5): 769–803

    Article  PubMed  CAS  Google Scholar 

  7. Wolters Kluwer Adis. R & D Insight. Salmeterol/fluticasone propionate: product information [online]. Available from URL: http://bi.adisinsight.com/frames.aspx [Accessed 2009 May 25]

  8. Kirby S, Falcoz C, Daniel MJ, et al. Salmeterol and fluticasone propionate given as a combination: lack of systemic pharmacodynamic and pharmacokinetic interactions. Eur J Clin Pharmacol 2001; 56: 781–91

    Article  PubMed  CAS  Google Scholar 

  9. Chung KF, Adcock IM. Combination therapy of long-acting B2-adrenoceptor agonists and corticosteroids for asthma. Treat Respir Med 2004; 3(5): 279–89

    Article  PubMed  CAS  Google Scholar 

  10. Koopmans JG, Lutter R, Jansen HM, et al. Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma. Thorax 2006 Apr; 61(4): 306–13

    Article  PubMed  CAS  Google Scholar 

  11. Houghton CM, Lawson N, Borrill ZL, et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respir Res 2007; 8: 52

    Article  PubMed  Google Scholar 

  12. Palmqvist M, Arvidsson P, Beckman O, et al. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001; 14: 29–34

    Article  CAS  Google Scholar 

  13. Aldington S, Williams M, Weatherall M, et al. Duration of action of the salmeterol/fluticasone combination inhaler administered in the evening: a randomized controlled trial in childhood asthma. Respirology 2006 Sep; 11(5): 638–42

    Article  PubMed  Google Scholar 

  14. Bleecker ER, Yancey SW, Baitinger LA, et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006 Oct; 118(4): 809–16

    Article  PubMed  CAS  Google Scholar 

  15. Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370: 2118–25

    Article  PubMed  CAS  Google Scholar 

  16. Bleecker ER, Nelson H, Corren J, et al. Arg16Gly polymorphism of the beta-(2)-adrenergic receptor gene does not modulate clinical response to salmeterol in subjects with asthma [abstract no. 554]. J Allergy Clin Immunol 2008 Feb; 121(2): S143

    Article  Google Scholar 

  17. Ortega H, Klotsman M, Yancey S, et al. Associations between genetic polymorphisms and withdrawals from controlled clinical trials in Caucasian and African American patients with asthma [abstract no. F24 plus poster]. Am J Respir Crit Care Med 2007 Apr 1; 175: A462

    Google Scholar 

  18. Kawai M, Kempsford R, Pullerits T, et al. Comparison of the efficacy of salmeterol/fluticasone propionate combination in Japanese and Caucasian asthmatics. Respir Med 2007 Dec; 101(12): 2488–94

    Article  PubMed  CAS  Google Scholar 

  19. Bailey W, Castro M, Matz J, et al. Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. Curr Med Res Opin 2008 Jun; 24(6): 1669–82

    Article  PubMed  CAS  Google Scholar 

  20. GlaxoSmithKline. Advair Diskus® 100/50, 250/50, 500/50 prescribing information [online]. Available from URL: http://us.gsk.com/products/assets/us_advair.pdf [Accessed 2009 May 24]

  21. European Medicines Agency. Seretide Diskus® 50/100, 50/250, 50/500 microgram dose inhalation powder [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/referral/seretideevohaler/SeretideEvohalerAnnexes%20I-II-II-en. pdf [Accessed 2009 Apr 3]

  22. Strand AM, Luckow A. Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone. Respir Med 2004 Oct; 98(10): 1008–15

    Article  PubMed  Google Scholar 

  23. Bergmann K-C, Lindemann L, Braun R, et al. Salmeterol/fluticasone propionate (50/250 μg) combination is superior to double dose fluticasone (500 μg) for the treatment of symptomatic moderate asthma. Swiss Med Wkly 2004 Jan 24; 134(3–4): 50–8

    PubMed  CAS  Google Scholar 

  24. Lundback B, Ronmark E, Lindberg A, et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir Med 2006 Jan; 100(1): 2–10

    Article  PubMed  Google Scholar 

  25. Godard P, Greillier P, Pigearias B, et al. Maintaining asthma control in persistent asthma: comparison of three strategies in a 6-month double-blind randomised study. Respir Med 2008 Aug; 102(8): 1124–31

    Article  PubMed  Google Scholar 

  26. Fitzgerald J-M, Boulet L-P, Follows RMA. The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther 2005 Apr; 27(4): 393–406

    Article  PubMed  CAS  Google Scholar 

  27. Dahl R, Chuchalin A, Gor D, et al. EXCEL: a randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respir Med 2006 Jul; 100(7): 1152–62

    Article  PubMed  Google Scholar 

  28. Adachi M, Aizawa H, Ishihara K, et al. Comparison of salmeterol/fluticasone propionate (FP) combination with FP+sustained release theophylline in moderate asthma patients. Respir Med 2008 Jul; 102(7): 1055–64

    Article  PubMed  Google Scholar 

  29. Papi A, Paggiaro P, Nicolini G, et al. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007 Oct; 62(10): 1182–8

    Article  PubMed  CAS  Google Scholar 

  30. Jarjour NN, Wilson SJ, Koenig SM, et al. Control of airway inflammation maintained at a lower steroid dose with 100/50 μg of fluticasone propionate/salmeterol. J Allergy Clin Immunol 2006 Jul; 118(1): 44–52

    Article  PubMed  CAS  Google Scholar 

  31. de Blic J, Ogorodova L, Klink R, et al. Salmeterol/fluticasone propionate vs double dose fluticasone propionate on lung function and asthma control in children. Pediatr Allergy Immunol. Epub 2009 Feb 20

  32. Van den Berg NJ, Ossip MS, Hederos CA, et al. Salmeterol/fluticasone propionate (50/100 μg) in combination in a Diskus™ inhaler (Seretide™) is effective and safe in children with asthma. Pediatr Pulmonol 2000; 30: 97–105

    Article  PubMed  Google Scholar 

  33. Maspero J, Guerra F, Cuevas F, et al. Efficacy and toler-ability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: a prospective, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2008 Aug; 30(8): 1492–504

    Article  PubMed  CAS  Google Scholar 

  34. American Lung Association Asthma Clinical Research Centers. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007 May 17; 356(20): 2027–39

    Article  Google Scholar 

  35. Pearlman D, Qaqundah P, Matz J, et al. Fluticasone propionate/salmeterol and exercise-induced asthma in children with persistent asthma. Pediatr Pulmonol 2009; 44(5): 429–35

    Article  PubMed  Google Scholar 

  36. Gappa M, Zachgo W, von Berg A, et al. Superior efficacy of the salmeterol/fluticasone 50 μg/100 μg combination compared to fluticasone 200 μg in children with uncontrolled asthma: the VIAPAED trial [abstract no. 3057]. 18th Annual Congress of the European Respiratory Society; 2008 Oct 4–8; Berlin

  37. Woodcock AA, Bagdonas A, Boonsawat W, et al. Improvement in asthma endpoints when aiming for total control: salmeterol/fluticasone propionate versus fluticasone propionate alone. Prim Care Respir J 2007 Jun; 16(3): 155–61

    Article  PubMed  Google Scholar 

  38. Pedersen SE, Bateman ED, Bousquet J, et al. Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study. J Allergy Clin Immunol 2007 Nov; 120(5): 1036–42

    Article  PubMed  CAS  Google Scholar 

  39. Lundback B, Ronmark E, Lindberg A, et al. Asthma control over 3 years in a real-life study. Respir Med 2009 Mar; 103(3): 348–55

    Article  PubMed  Google Scholar 

  40. Stanford RH, Fuhlbrigge A, Riedel A, et al. An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes. Curr Med Res Opin 2008 Oct; 24(11): 3141–8

    Article  PubMed  CAS  Google Scholar 

  41. O’Connor RD, Carranza Rosenzweig JR, Stanford RH, et al. Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens. Ann Allergy Asthma Immunol 2005 Dec; 95(6): 535–40

    Article  PubMed  Google Scholar 

  42. Nguyen WT, Stewart C, Fisher K, et al. Maintenance asthma treatment with fluticasone/salmeterol combination via Diskus: effect on outcomes in inner-city children enrolled in TennCare. Allergy Asthma Proc 2005 Mar–Apr; 26(2): 129–34

    PubMed  Google Scholar 

  43. O’Connor RD, Stanford RH, Yeh W, et al. Observational study of the association of fluticasone propionate/salmeterol via a single device and inhaled corticosteroid use in children on asthma related emergency department and hospitalization visits [abstract no. 22]. J Allergy Clin Immunol 2008 Feb; 121 Suppl. 2A: 6

    Article  Google Scholar 

  44. Delea TE, Stanford RH, Hagiwara M. Observational study of outcomes with fluticasone propionate (FP)/salmeterol in a single device vs. doubling the dose of FP in asthma patients not adequately controlled with FP alone [abstract no. C32]. Am J Respir Crit Care Med 2008 May 16; 177: A609

    Google Scholar 

  45. Wang M-T, Skrepnek GH, Armstrong E, et al. Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma. Curr Med Res Opin 2008; 24(3): 859–67

    Article  PubMed  CAS  Google Scholar 

  46. Chan J, Hui RL, Spence MM. Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids. J Manag Care Pharm 2007 Jan; 13(1): 21–7

    PubMed  Google Scholar 

  47. Barnes NC, Jacques L, Goldfrad C, et al. Initiation of maintenance treatment with salmeterol/fluticasone propionate 50/100 μg bd versus fluticasone propionate 100 μg bd alone in patients with persistent asthma: integrated analysis of four randomised trials. Respir Med 2007 Nov; 101(11): 2358–65

    Article  PubMed  CAS  Google Scholar 

  48. Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008 Jul; 149(1): 33–42

    PubMed  Google Scholar 

  49. Nelson HS, Chapman KR, Pyke SD, et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 2003 Jul; 112(1): 29–36

    Article  PubMed  CAS  Google Scholar 

  50. Ortega H, Jain R, Emmett A. Subjects receiving fluticasone propionate/salmeterol 100/50mcg BID have significantly fewer asthma attacks vs montelukast 10 mg QD +/− fluticasone propionate 100 mcg BID: retrospective analysis of 4 randomized studies [abstract no. F80 plus poster]. Am J Respir Crit Care Med 2007 Apr; 175 Suppl.: A495

    Google Scholar 

  51. GlaxoSmithKline. Sponsor Briefing Statement. Advair Diskus, Advair HFA. inhalation aerosol, Serevent, Servevent Diskus [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-04-GSK.pdf [Accessed 2009 Jul 14]

  52. Murray J, Rosenthal R, Somerville L, et al. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting β2-agonists. Ann Allergy Asthma Immunol 2004 Oct; 93(4): 351–9

    Article  PubMed  CAS  Google Scholar 

  53. Nelson HS, Wolfe JD, Gross G, et al. Efficacy and safety of fluticasone propionate 44 μg/salmeterol 21 μg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. Ann Allergy Asthma Immunol 2003 Sep; 91(3): 263–9

    Article  PubMed  CAS  Google Scholar 

  54. Rojas RA, Paluga I, Goldfrad CH, et al. Initiation of maintenance therapy with salmeterol/fluticasone propionate combination therapy in moderate asthma: a comparison with fluticasone propionate. J Asthma 2007 Jul; 44(6): 437–41

    Article  PubMed  CAS  Google Scholar 

  55. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma controL study. Am J Respir Crit Care Med 2004 Oct; 170(8): 836–44

    Article  PubMed  Google Scholar 

  56. Calhoun WJ, Nelson HS, Nathan RA, et al. Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting β2-agonists alone. Am J Respir Crit Care Med 2001 Sep; 164: 759–63

    PubMed  CAS  Google Scholar 

  57. Pearlman DS, White MV, Lieberman AK, et al. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Ann Allergy Asthma Immunol 2002 Feb; 88: 227–35

    Article  PubMed  CAS  Google Scholar 

  58. Kerwin EM, Nathan RA, Meltzer EO, et al. Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily. Respir Med 2008 Apr; 102(4): 495–504

    Article  PubMed  Google Scholar 

  59. Nathan RA, Rooklin A, Schoaf L, et al. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. Clin Ther 2006 Jan; 28(1): 73–85

    Article  PubMed  CAS  Google Scholar 

  60. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161: 527–34

    PubMed  CAS  Google Scholar 

  61. Busse W, Koenig SM, Oppenheimer J, et al. Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 mg administered twice daily. J Allergy Clin Immunol 2003 Jan; 111(1): 57–65

    Article  PubMed  CAS  Google Scholar 

  62. Weiler JM, Nathan RA, Rupp NT, et al. Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. Ann Allergy Asthma Immunol 2005 Jan; 94(1): 65–72

    Article  PubMed  CAS  Google Scholar 

  63. Stauffer J, Watikus-Edwards K, Yancey S, et al. Fluticasone propionate/salmeterol administered via Diskus® provides protection against activity-induced bronchospasm in children and adolescents with persistent asthma [abstract no. P103]. Ann Allergy Asthma Immunol 2007 Jan; 98 (1 Suppl. 1): A62

    Google Scholar 

  64. Aubier M, Pieters WR, Schlösser NJJ, et al. Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93: 876–84

    Article  PubMed  CAS  Google Scholar 

  65. Chapman KR, Ringdal N, Backer V, et al. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 1999 Jan; 6(1): 45–51

    PubMed  CAS  Google Scholar 

  66. Bateman ED, Britton M, Carrillo J, et al. Salmeterol/fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma. Clin Drug Invest 1998; 16(3): 193–201

    Article  CAS  Google Scholar 

  67. Ringdal N, Eliraz A, Pruzinec P, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003 Mar; 97: 234–41

    Article  PubMed  CAS  Google Scholar 

  68. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000 Dec; 106(6): 1088–95

    Article  PubMed  CAS  Google Scholar 

  69. Jenkins C, Woolcock AJ, Saarelainen P, et al. Salmeterol/fluticasone propionate combination therapy 50/250 μg twice daily is more effective than budesonide 800 μg twice daily in treating moderate to severe asthma. Respir Med 2000; 94: 715–23

    Article  PubMed  CAS  Google Scholar 

  70. Johansson G, McIvor RA, D’Ambrosio FP, et al. Comparison of salmeterol/fluticasone propionate combination with budesonide in patients with mild-to-moderate asthma. Clin Drug Invest 2001; 21(9): 633–42

    Article  CAS  Google Scholar 

  71. Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 2007 Dec; 101(12): 2437–46

    Article  Google Scholar 

  72. Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007 May; 61(5): 725–36

    Article  PubMed  CAS  Google Scholar 

  73. Aalbers R, Backer V, Kava TTK, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004; 20(2): 225–40

    Article  PubMed  CAS  Google Scholar 

  74. Ringdal N, Chuchalin A, Chovan L, et al. Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide™ (50/250 μg bd Diskus™ vs. formoterol (12μg bd) and budesonide (800 μg bd) given concurrently (both via Turbuhaler™) in patients with moderate-to-severe asthma. Respir Med 2002 Nov; 96: 851–61

    CAS  Google Scholar 

  75. Vogelmeier C, D’Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26(5): 819–28

    Article  PubMed  CAS  Google Scholar 

  76. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 105 (6 Pt 1): 1108–16

    Article  PubMed  CAS  Google Scholar 

  77. Pearlman DS, Peden D, Condemi JJ, et al. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. J Asthma 2004; 41(8): 797–806

    Article  PubMed  CAS  Google Scholar 

  78. Busse WW, Shah SR, Somerville L, et al. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. J Allergy Clin Immunol 2008 Jun; 121(6): 1407–14

    Article  PubMed  CAS  Google Scholar 

  79. Bateman ED, Jacques L, Goldfrad C, et al. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol 2006 Mar; 117(3): 563–70

    Article  PubMed  CAS  Google Scholar 

  80. Koenig SM, Ostrom N, Pearlman D, et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50mcg Diskus are “steppeddown”. J Asthma 2008 Oct; 45(8): 681–7

    Article  PubMed  CAS  Google Scholar 

  81. You-Ning L, Humphries M, Du X, et al. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. Int J Clin Pract 2005 Jul; 59(7): 754–9

    Article  PubMed  CAS  Google Scholar 

  82. Bateman ED, Silins V, Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 μg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir Med 2001 Feb;95: 136–46

    Article  PubMed  CAS  Google Scholar 

  83. van Noord JA, Lill H, Carrillo Diaz T, et al. Clinical equivalence of a salmeterol/fluticasone propionate combination product (50/500 μg) delivered via a chlorofluorocarbon-free metered-dose inhaler with the Diskus™ in patients with moderate to severe asthma. Clin Drug Invest 2001; 21(4): 243–55

    Article  Google Scholar 

  84. Bracamonte T, Schauer U, Emeryk A, et al. Efficacy and safety of salmeterol/fluticasone propionate combination delivered by the Diskus™ or pressurised metered-dose inhaler in children with asthma. Clin Drug Invest 2005; 25(1): 1–11

    Article  CAS  Google Scholar 

  85. Bateman ED, Bousquet J, Keech ML, et al. The correlation between asthma control and health status: the GOAL study. Eur Respir J 2007 Jan; 29(1): 56–63

    Article  PubMed  CAS  Google Scholar 

  86. Price DB, Williams AE, Yoxall S. Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life. Respir Res 2007; 8: 46

    Article  PubMed  Google Scholar 

  87. O’Connor RD, Patrick DL, Parasuraman B, et al. Patient satisfaction during treatment with adjustable-dose budesonide/formoterol pressurized metered-dose inhaler (BUD/FM pMDI), fixed-dose BUD/FM pMDI, and fixed-dose fluticasone/salmeterol dry powder inhaler (FP/SM DPI) [abstract plus poster no. A13]. Am J Respir Crit Care Med 2008 May; 177: 609

    Google Scholar 

  88. O’Connor RD, Gilmore AS, Manjunath R, et al. Comparing outcomes in patients with persistent asthma: a registry of two therapeutic alternatives. Curr Med Res Opin 2006 Mar; 22(3): 453–61

    Article  PubMed  Google Scholar 

  89. Sorkness CA, Lemanske RF, Mauger DT, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2007 Jan; 119(1): 64–72

    Article  PubMed  Google Scholar 

  90. Cowie RL, Boulet LP, Keith PK, et al. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study. Clin Ther 2007 Jul; 29(7): 1390–402

    Article  PubMed  CAS  Google Scholar 

  91. Malone R, LaForce C, Nimmagadda S, et al. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Ann Allergy Asthma Immunol 2005 Jul; 95(1): 66–71

    Article  PubMed  CAS  Google Scholar 

  92. Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter asthma research trial. Chest 2006 Jan; 129(1): 15–26

    Article  PubMed  CAS  Google Scholar 

  93. American College of Allergy, Asthma and Immunology. Guidelines for the diagnosis and management of asthma [online]. Available from URL: http://www.acaai.org/member/Practice_Resources/guidelines.htm [Accessed 2009 Jun 12]

  94. Lyseng-Williamson KA, Plosker GL. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. Pharmacoeconomics 2003; 21(13): 951–89

    Article  PubMed  CAS  Google Scholar 

  95. Briggs AH, Bousquet J, Wallace MV, et al. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy 2006 May; 61(5): 531–6

    Article  PubMed  CAS  Google Scholar 

  96. Borker R, Emmett A, Jhingran P, et al. Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves. Ann Allergy Asthma Immunol 2005 Aug; 95(2): 181–9

    Article  PubMed  Google Scholar 

  97. Johansson G, Andreasson EB, Larsson PE, et al. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics 2006; 24(7): 695–708

    Article  PubMed  CAS  Google Scholar 

  98. Miller E, Sears MR, McIvor A, et al. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Can Respir J 2007 Jul; 14(5): 269–75

    PubMed  Google Scholar 

  99. Shih Y-CT, Mauskopf J, Borker R. A cost-effectiveness analysis of first-line controller therapies for persistent asthma. Pharmacoeconomics 2007; 25(7): 577–90

    Article  PubMed  Google Scholar 

  100. Doull I, Price D, Thomas M, et al. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma. Curr Med Res Opin 2007 May; 23(5): 1147–59

    Article  PubMed  CAS  Google Scholar 

  101. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329: 224–7

    Article  PubMed  Google Scholar 

  102. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. 2008 May, revised 2009 [online]. Available from URL: http://www.sign.ac.uk/pdf/sign101.pdf [Accessed 2009 Jun 12]

  103. Chapman KR, Boulet LP, Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008; 31(2): 320–5

    Article  PubMed  CAS  Google Scholar 

  104. Bellamy D, Harris T. Poor perceptions and expectations of asthma control: results of the International Control of Asthma Symptoms (ICAS) survey of patients and general practitioners. Prim Care Respir J 2005; 14: 252–8

    Article  PubMed  Google Scholar 

  105. Haughney J, Barnes G, Partridge M, et al. The Living & Breathing Study: a study of patients’ views of asthma and its treatment. Prim Care Respir J 2004; 13: 28–35

    Article  PubMed  Google Scholar 

  106. Koenig SM, Murray JJ, Wolfe J, et al. Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma? Respir Med 2008; 102: 665–73

    Article  PubMed  Google Scholar 

  107. Lasserson TJ, Cates CJ, Ferrara G, et al. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev 2008; (3): CD004106

  108. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007 Mar; 29(3): 587–95

    Article  PubMed  CAS  Google Scholar 

  109. Lundback B, Dahl R. Assessment of asthma control and its impact on optimal treatment strategy. Allergy 2007 Jun; 62(6): 611–9

    Article  PubMed  CAS  Google Scholar 

  110. Katz PP, Yelin EH, Eisner MD, et al. Perceived control of asthma and quality of life among adults with asthma. Ann Allergy Asthma Immunol 2002; 89(3): 251–8

    Article  PubMed  Google Scholar 

  111. Delea TE, Hagiwara M, Stanford RH, et al. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma. Clin Ther 2008 Mar; 30(3): 560–71

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kate McKeage.

Additional information

Various sections of the manuscript reviewed by: S. Beggs, Department of Paediatrics, Royal Hobart Hospital, Hobart, Tasmania, Australia; W. Boonsawat, Department of Medicine, Khon Kaen University, Khon Kaen, Thailand; T.J. Craig, Division of Pulmonary, Allergy and Critical Care, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA; T.W. de Vries, Department of Pediatrics, Medical Centre Leeuwarden, Leeuwarden, the Netherlands; R. Dinwiddie, Respiratory Unit, Great Ormond Street Hospital for Children NHS Trust, London, England; B. Lundback, Department of Respiratory Medicine, University of Göteborg, Göteborg, Sweden.

Data Selection

Sources: Medical literature published in any language since 1980 on ‘salmeterol/fluticasone’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Wolters Kluwer Health | Adis). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: MEDLINE, EMBASE and AdisBase search terms were ‘salmeterol/fluticasone propionate’ or ‘fluticasone/salmeterol’ and ‘asthma’. Searches were last updated 3 August 2009.

Selection: Studies in patients with asthma who received salmeterol/fluticasone propionate. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Salmeterol, fluticasone propionate, salmeterol/fluticasone propionate, asthma, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McKeage, K., Keam, S.J. Salmeterol/Fluticasone Propionate. Drugs 69, 1799–1828 (2009). https://doi.org/10.2165/11202210-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11202210-000000000-00000

Keywords

Navigation